Another Elagolix Study Supports AbbVie's NDA, But Which Dose?

A second positive Phase III clinical trial for AbbVie Inc.'s elagolix in the treatment of endometriosis pain in premenopausal women supports a new drug application (NDA) submission to the US FDA in 2017, but it's unknown whether both doses tested in the trials will be viable in the real world.